Georgia's Online Cancer Information Center

Find A Clinical Trial

Financial Navigation Program to Improve Understanding and Management of Financial Aspects of Cancer Care for Patients

Status
Active
Cancer Type
Solid Tumor
Unknown Primary
Trial Phase
Eligibility
18 Years and older, Male and Female
Study Type
Health services research
NCT ID
NCT04960787
Protocol IDs
S1912CD (primary)
S1912CD
SWOG-S1912CD
NCI-2021-00579
Study Sponsor
SWOG

Summary

This clinical trial examines a financial navigation program in helping patients understand and better manage the financial aspects of cancer care. Cancer patients may be at high risk for financial problems because of the cost of cancer treatment. A financial navigator is a person or team who work with patients and their families to help them reduce stress or hardship related to the cost of cancer treatment. Financial navigators help patients understand their out-of-pocket expenses and what their health insurance plans may cover. Financial navigation may also help patients set up payment plans, find cost-saving methods for treatments, and improve access to healthcare services that the patient needs. Providing financial navigation to patients may help reduce financial worries and improve quality of life.

Objectives

PRIMARY OBJECTIVE:
I. To determine whether a proactive financial navigation program for patients planning to receive anti-cancer treatment decreases the risk of material financial hardship over 12 months among patients with newly diagnosed or recurrent metastatic solid tumor, or a newly diagnosed hematologic malignancy.

SECONDARY OBJECTIVES:
I. To examine whether proactive financial navigation improves patient quality of life.
II. To examine whether proactive financial navigation decreases financial worry among patients relative to usual care and explore the extent to which financial worry correlates with financial hardship.
III. To explore whether the proactive financial navigation intervention leads to decreased cost-related medication nonadherence and fewer patient emergency department (ED) visits and unplanned hospital admissions.

ADDITIONAL OBJECTIVES:
I. To explore the impact of proactive financial navigation on spouse/partner caregiver financial hardship, quality of life, and caregiver burden and evaluate the concordance between patient and caregiver credit data.
II. To explore the utilization of financial navigation services by younger, financially fragile, and lower income patients and households and evaluate the moderator effect of age, financial fragility, and income on the impact of the proactive financial navigation intervention.

OUTLINE: Patients and spouses/partners are randomized to 1 of 2 groups.

GROUP I: Participants receive financial literacy training consisting of watching online educational videos over 2-8 minutes. Participants also complete questionnaires over 30-60 minutes about education, employment, finances (assets, debt), insurance, and quality of life (financial worry) and have credit reports assessed at baseline and 3, 6, and 12 months.

GROUP II: Participants receive financial literacy training consisting of watching online educational videos, developed by Consumer Education and Training Services (CENTS) over 2-8 minutes. Participants also meet with Patient Advocate Foundation (PAF) counselor over approximately 1 hour every month for 6 months. Participants also complete questionnaires over 30-60 minutes about education, employment, finances (assets, debt), insurance, and quality of life (financial worry) and have credit reports assessed at baseline and 3, 6, and 12 months.

Eligibility

  1. Patients must have a diagnosis of a metastatic or stage IV solid tumor or a hematologic malignancy and must receive anti-cancer treatment (i.e. chemotherapy, hormonal therapy, targeted therapy, biologic therapy, immune therapy, bone marrow transplant). Registration must occur within 180 days after diagnosis of metastatic or stage IV solid tumor or treatment-requiring hematologic malignancy. Patients with indolent hematologic diseases undergoing observation alone are not eligible; patients with previously diagnosed hematologic cancers progressed to the point of requiring systemic therapy are eligible, so long as the progression occurred within the previous 180 days. Biopsy confirmation of metastatic disease is not required
  2. Patients with recurrent solid tumors will be allowed as long as 1) this is the first presentation of metastatic or stage IV disease and 2) the diagnosis of the metastasis is at least 180 days (6 months) after the diagnosis date of the previous earlier stage cancer
  3. Patients with a history of secondary malignancy are allowed as long as they were not diagnosed within the previous 24 months, and are disease-free. Patients with adequately treated basal cell or squamous cell skin cancer, and in situ cervical cancer at any point prior to enrollment are eligible
  4. Patients who have started anti-cancer treatment for the current diagnosis must have started within 90 days prior to registration
  5. Patients who are planning to start anti-cancer treatment for the current diagnosis must start within (=<) 30 days after registration
  6. Patients are allowed to be co-enrolled on other clinical trials (including non-treatment studies and studies that may or may not include investigational drugs)
  7. Patients may not be enrolled in hospice care at the time of registration
  8. Patients must be at least 18 years of age
  9. Patients must have a Zubrod performance status of 0-2
  10. Patients must complete the baseline patient reported outcomes (PRO) questionnaires prior to registration and must be able to complete questionnaires in English or Spanish
  11. Patients must provide their full name, primary address in the United States (U.S.), birth date and social security number at registration for the purposes of accessing credit report data. (This may be obtained directly from the patient, study questionnaires, or the medical record)
  12. Patients must provide email and/or telephone number for the purposes of being contacted by financial navigators
  13. Caregiver participation is optional
  14. Spouse/partner caregivers must be living in the same household as the eligible patient and be either legally married, in a common law marriage, or be an intimate partner/significant other of the patient * The study team acknowledges that other types of caregivers may also face financial hardship following a patient’s cancer diagnosis and may similarly benefit from financial education and navigation. The decision to focus solely on spouse or partner caregivers was scientific, to understand how caregivers who share household finances experience financial hardship
  15. Non-spouse/partner caregivers such as friends, adult children, parents, or other relatives living in the same household as the patient are not eligible
  16. Spouse/partner caregivers must be at least 18 years of age
  17. Spouse/partner caregivers must provide their full name, primary address in the U.S., birth date and social security number at registration for the purposes of accessing credit report data
  18. Spouse/partner caregivers must provide email and/or telephone number for the purposes of being contacted by the financial navigators
  19. Spouse/partner caregivers must be able to complete questionnaires in English or Spanish and must complete the baseline questionnaires prior to patient registration
  20. Participants (patients and caregivers, when participating) must sign and give written informed consent in accordance with institutional and federal guidelines. Use of legally-authorized representative is not permissible for this study. Documentation of informed consent via remote consent is permissible
  21. As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.